|
|
|
| Advances in the application of positron emission tomography in the diagnosis and treatment of gynecological malignancies |
| LIU Xuefen, LI Yuan |
| Department of Gynecology and Obstetrics, Hai’an Hospital of Traditional Chinese Medicine Affiliated to Yangzhou University Medical School, Hai’an 226600 China |
|
|
|
|
Abstract Positron emission tomography (PET) has been used for the diagnosis of gynecological malignancies and is superior to conventional imaging tools in detecting metastatic lesions, diagnosing local recurrence, and evaluating treatment outcome. Compared with the in vitro assessment of tumor biopsy materials, PET imaging has advantages in measuring in vivo tumor behaviors, characterizing overall tumor burden, and capturing the phenotypic heterogeneity of tumors. PET imaging provides precision data on tumor staging and recurrence through integrating the anatomic and functional data of metabolic features, thereby achieving the high-quality assessment of gynecological malignancies. This article reviews the advances in the application of PET imaging in the diagnosis and treatment of cervical cancer, ovarian cancer, and endometrial carcinoma.
|
|
Received: 06 May 2022
|
|
|
|
|
|
[1] Chen H, He Y, Wen X, et al. SOX9: Advances in gynecological malignancies[J]. Front Oncol, 2021, 11: 768264. DOI: 10.3389/fonc.2021.768264
[2] Arora S, Narayan P, Ison G, et al. U.S. FDA drug approvals for gynecological malignancies: A decade in review[J]. Clin Cancer Res, 2022, 28(6): 1058-1071. DOI: 10.1158/1078-0432.CCR-21-2599
[3] Wang D, He J, Dong J, et al. The HIPPO pathway in gynecological malignancies[J]. Am J Cancer Res, 2020, 10(2): 610-629
[4] Virarkar M, Viswanathan C, Iyer R, et al. The role of positron emission tomography/magnetic resonance imaging in gynecological malignancies[J]. J Comput Assist Tomogr, 2019, 43(6): 825-834. DOI: 10.1097/RCT.0000000000000918
[5] Sonni I, Iagaru A. PET Imaging toward individualized management of urologic and gynecologic malignancies[J]. PET Clin, 2016, 11(3): 261-72. DOI: 10.1016/j.cpet.2016.02.007
[6] Cohen D, Hazut Krauthammer S, Levine C, et al. Staging cervical cancer using PET-CT and PET-MRI[J]. Harefuah, 2021, 160(7): 442-447
[7] Gandy N, Arshad MA, Park WE, et al. FDG-PET imaging in cervical cancer[J]. Semin Nucl Med, 2019, 49(6): 461-470. DOI: 10.1053/j.semnuclmed.2019.06.007
[8] Ishiguro T, Nishikawa N, Ishii S, et al. PET/MR imaging for the evaluation of cervical cancer during pregnancy[J]. BMC Pregnancy Childbirth, 2021, 21(1): 288. 10.1186/s12884-021-03766-w.
[9] Cohen PA, Jhingran A, Oaknin A, et al. Cervical cancer[J]. Lancet, 2019, 393(10167): 169-182. DOI: 10.1016/S0140-6736(18)32470-X
[10] Zhu Y, Shen B, Pei X, et al. CT, MRI, and PET imaging features in cervical cancer staging and lymph node metastasis[J]. Am J Transl Res, 2021, 13(9): 10536-10544
[11] Yang Z, Wu JR, Wei LL, et al. High standardized uptake values of 18F-FDG PET/CT imaging but not MRI correlates to pathology findings in patients with cervical cancer[J]. Hell J Nucl Med, 2019, 22: 96-102. DOI: 10.1967/s002449911001
[12] Fischerová D, Cibula D. The role of ultrasound in primary workup of cervical cancer staging (ESGO, ESTRO, ESP cervical cancer guidelines)[J]. Ceska Gynekol, 2019, 84: 40-48
[13] Schwartz M, Gavane SC, Bou-Ayache J, et al. Feasibility and diagnostic performance of hybrid PET/MRI compared with PET/CT for gynecological malignancies: a prospective pilot study[J]. Abdom Radiol (NY), 2018, 43: 3462-3467. DOI: 10.1007/s00261-018-1665-2
[14] Min LA, Vogel WV, Lahaye MJ, et al. Integrated versus separate reading of F-18 FDG-PET/CT and MRI for abdominal malignancies-effect on staging outcomes and diagnostic confidence[J]. Eur Radiol, 2019, 29(12): 6900-6910. DOI: 10.1007/s00330-019-06253-1
[15] Makvandi M, Pantel A, Schwartz L, et al. A PET imaging agent for evaluating PARP-1 expression in ovarian cancer[J]. J Clin Invest, 2018, 128(5): 2116-2126. DOI: 10.1172/JCI97992
[16] Boyle AJ, Tong J, Zoghbi SS, et al. Repurposing 11C-PS13 for PET imaging of cyclooxygenase-1 in ovarian cancer xenograft mouse models[J]. J Nucl Med, 2021, 62(5): 665-668. DOI: 10.2967/jnumed.120.249367
[17] Torre LA, Trabert B, DeSantis CE, et al. Ovarian cancer statistics, 2018[J]. CA Cancer J Clin, 2018, 68(4): 284-296. DOI: 10.3322/caac.21456
[18] Khiewvan B, Torigian DA, Emamzadehfard S, et al. An update on the role of PET/CT and PET/MRI in ovarian cancer[J]. Eur J Nucl Med Mol Imaging, 2017, 44(6): 1079-1091. DOI: 10.1007/s00259-017-3638-z
[19] Kemppainen J, Hynninen J, Virtanen J, et al. PET/CT for evaluation of ovarian cancer[J]. Semin Nucl Med, 2019, 49(6): 484-492. DOI: 10.1053/j.semnuclmed.2019.06.010
[20] Shen G, Kuang A. Recurrent ovarian cancer presenting as a solitary chest wall metastasis revealed by FDG PET/CT[J]. Clin Nucl Med, 2022, 47(4): 365-366. DOI: 10.1097/RLU.0000000000003958
[21] Lee SI, Catalano OA, Dehdashti F. Evaluation of gynecologic cancer with MR imaging, 18F-FDG PET/CT, and PET/MR imaging[J]. J Nucl Med, 2015, 56(3): 436-43. DOI: 10.2967/jnumed.114.145011
[22] Esteves FP, Amorim BJ, Martello M, et al. Relapsed ovarian cancer-diagnosis using 18F-FDG PET/CT; 4[J]. Rev Assoc Med Bras, 2019, 65(4): 509-517. DOI: 10.1590/1806-9282.65.4.509
[23] Huang R, Pu Y, Huang S, et al. FAPI-PET/CT in cancer imaging: A potential novel molecule of the century[J]. Front Oncol, 2022, 12: 854658. DOI: 10.3389/fonc.2022.854658
[24] KubečekO, LacoJ, ŠpačekJ, et al. The pathogenesis, diagnosis, and management of metastatic tumors to the ovary: a comprehensive review[J]. Clin Exp Metastasis, 2017, 34(5): 295-307. DOI: 10.1007/s10585-017-9856-8
[25] Ironi G, Mapelli P, Bergamini A, et al. Hybrid PET/MRI in staging endometrial cancer: Diagnostic and predictive value in a prospective cohort[J]. Clin Nucl Med, 2022, 47(3): e221-e229. DOI: 10.1097/RLU.0000000000004064
[26] Dewulf J, Vangestel C, Verhoeven Y, et al. Immuno-PET molecular imaging of RANKL in cancer[J]. Cancers (Basel), 2021, 13(9): 2166. DOI: 10.3390/cancers13092166
[27] Jani AB, Schreibmann E, Goyal S, et al. 18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial[J]. Lancet, 2021, 97(10288): 1895-1904. DOI: 10.1016/S0140-6736(21)00581-X
[28] Queiroz MA, Kubik-Huch RA, Hauser N, et al. PET/MRI and PET/CT in advanced gynaecological tumours: initial experience and comparison[J]. Eur Radiol, 2015, 25(8): 2222-2230. DOI: 10.1007/s00330-015-3657-8
[29] Kilcoyne A, Chow DZ, Lee SI. FDG-PET for assessment of endometrial and vulvar cancer[J]. Semin Nucl Med, 2019, 49(6): 471-483. DOI: 10.1053/j.semnuclmed.2019.06.011
[30] Yanarateş A, Budak E. Prognostic role of PET/CT in endometrial cancer[J]. Ginekol Pol, 2019, 90(9): 491-495. DOI: 10.5603/GP.2019.0085
[31] Sallée C, Margueritte F, Gouy S, et al. FDG-PET/CT and para-aortic staging in endometrial cancer. A French multicentric study[J]. J Clin Med, 2021, 10(8): 1746. DOI: 10.3390/jcm10081746
[32] Xu X, Li N, Chen Y, et al. Diagnostic efficacy of MRI for pre-operative assessment of ovarian malignancy in endometrial carcinoma: A decision tree analysis[J]. Magn Reson Imaging, 2019, 57: 285-292. DOI: 10.1016/j.mri.2018.12.008
[33] Çermik TF, Ergül N, Yılmaz B, et al. Tumor imaging with 68Ga-DOTA-FAPI-04 PET/CT: comparison with 18F-FDG PET/CT in 22 different cancer types[J]. Clin Nucl Med, 2022, 47(4): e333-e339. DOI: 10.1097/RLU.0000000000004073
[34] Damuka N, Solingapuram Sai KK. Method to development of PET radiopharmaceutical for cancer imaging[M]//Deep G. Cancer Biomarkers: Methods and Protocols. New York: Humana, 2022, 2413: 13-22. DOI: 10.1007/978-1-0716-1896-7_3.
[35] Wang T, Sun H, Han F, et al. Evaluation of parametrial infiltration in cervical cancer with voxel-based segmentation of integrated 18F-FDG PET/MRI images: a preliminary study[J]. Eur J Radiol, 2019, 118: 147-152. DOI: 10.1016/j.ejrad.2019.07.020
|
|
|
|
